Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 530163 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kerala Ayurveda Ltd is a below average quality company.
The key valuation ratios of Kerala Ayurveda Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kerala Ayurveda Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 2.2% | 2.5% | 3.2% | 4.1% | 4.8% | 2.4% | 2.6% | -0.9% | 6.9% | 5.7% | - |
| Value Creation Index ⓘ | -0.8 | -0.8 | -0.8 | -0.7 | -0.7 | -0.8 | -0.8 | -1.1 | -0.5 | -0.6 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 25.6 | 28.3 | 32.6 | 39.6 | 43.8 | 46.5 | 53.7 | 43.2 | 55.8 | 63.3 | 67 |
| Sales YoY Gr. | - | 10.7% | 15.1% | 21.7% | 10.5% | 6.2% | 15.5% | -19.5% | 29.2% | 13.4% | - |
| Adj EPS ⓘ | 0.8 | 1.1 | 1.6 | 2.1 | 2.2 | 0.3 | 0.8 | -4.7 | 0.8 | 0.9 | 2.1 |
| YoY Gr. | - | 25% | 56.2% | 27.4% | 4.3% | -86.7% | 186.2% | -665.1% | NA | 2.4% | - |
| BVPS (₹) ⓘ | 12.7 | 13.2 | 14.9 | 14.1 | 16.7 | 12.8 | 11 | 6.7 | 7.8 | 11.1 | 33.6 |
| Adj Net Profit ⓘ | 0.9 | 1.1 | 1.7 | 2.2 | 2.3 | 0.3 | 0.9 | -5 | 0.9 | 0.9 | 2 |
| Cash Flow from Ops. ⓘ | -0.1 | 0.3 | 2.5 | 1.5 | -10.9 | 9.3 | 4.7 | -0.9 | 8.8 | 9.1 | - |
| Debt/CF from Ops. ⓘ | -619.4 | 230.3 | 25.9 | 33.9 | -6.4 | 6 | 12.3 | -72.3 | 7 | 6.9 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 10.6% | 7.7% | 5.7% | 13.4% | ||||
| Adj EPS ⓘ | 0.3% | -17% | 1.2% | 2.4% | ||||
| BVPSⓘ | -1.6% | -8% | 0% | 41.3% | ||||
| Share Price | 26.9% | 31.3% | 71.9% | 175.5% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 6.8 | 8 | 11.7 | 14.5 | 14.2 | 2 | 6.2 | -40.1 | 8.4 | 7.1 | 9.3 |
| Op. Profit Mgn % ⓘ | 11.2 | 11.5 | 12.6 | 12.1 | 12.9 | 6.5 | 5.8 | 0.5 | 13.9 | 7.5 | 7.4 |
| Net Profit Mgn % ⓘ | 3.5 | 3.9 | 5.3 | 5.6 | 5.3 | 0.7 | 1.6 | -11.5 | 1.6 | 1.4 | 3.7 |
| Debt to Equity ⓘ | 4.5 | 4.6 | 4.1 | 3.5 | 3.9 | 4.2 | 5 | 9.4 | 7.4 | 5.4 | - |
| Working Cap Days ⓘ | 596 | 587 | 543 | 432 | 415 | 421 | 329 | 422 | 320 | 283 | 76 |
| Cash Conv. Cycle ⓘ | 75 | 82 | 83 | 99 | 105 | 107 | 94 | 112 | 79 | 75 | -24 |
Return on Equity has increased versus last 3 years average to 9.30%
Debt to equity has declined versus last 3 years average to 5.35
Sales growth is good in last 4 quarters at 13.75%
Sales growth has been subdued in last 3 years 5.65%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.1 | -0.9 |
| TTM Sales (₹ Cr.) | 67 | 100 |
| BVPS (₹.) ⓘ | 33.6 | 24.7 |
| Reserves (₹ Cr.) ⓘ | 31 | 21 |
| P/BV ⓘ | 7.78 | 10.55 |
| PE ⓘ | 126.22 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 82.62 / 329.75 |
| All Time Low / High (₹) | 1.40 / 329.75 |
| Market Cap (₹ Cr.) | 314 |
| Equity (₹ Cr.) | 12 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 47.5 |
| Pledged * | 100.00 | 100.00 | 100.00 | 0.00 | 100.00 | 100.00 | 46.55 | 8.09 | 7.45 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26 | 28 | 33 | 40 | 44 | 46 | 54 | 43 | 56 | 63 |
| Operating Expenses ⓘ | 23 | 25 | 28 | 35 | 38 | 43 | 51 | 43 | 48 | 59 |
| Manufacturing Costs | 4 | 5 | 5 | 5 | 6 | 7 | 8 | 6 | 8 | 9 |
| Material Costs | 4 | 6 | 7 | 7 | 8 | 10 | 11 | 12 | 13 | 14 |
| Employee Cost | 8 | 9 | 11 | 11 | 13 | 14 | 16 | 13 | 12 | 16 |
| Other Costs ⓘ | 6 | 5 | 6 | 11 | 12 | 13 | 16 | 12 | 15 | 19 |
| Operating Profit ⓘ | 3 | 3 | 4 | 5 | 6 | 3 | 3 | 0 | 8 | 5 |
| Operating Profit Margin (%) | 11.2% | 11.5% | 12.6% | 12.1% | 12.9% | 6.5% | 5.8% | 0.5% | 13.9% | 7.5% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 6 | 6 | 5 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 |
| Profit Before Tax ⓘ | 1 | 2 | 2 | 3 | 3 | 2 | 1 | -7 | 1 | 2 |
| Tax ⓘ | 0 | 0 | 1 | 1 | 1 | 1 | 0 | -2 | 0 | -1 |
| Profit After Tax | 1 | 1 | 2 | 2 | 2 | 1 | 1 | -5 | 1 | 3 |
| PAT Margin (%) | 4.0% | 3.9% | 5.3% | 5.6% | 5.3% | 2.6% | 1.6% | -11.5% | 1.6% | 4.6% |
| Adjusted EPS (₹) | 1.0 | 1.1 | 1.6 | 2.1 | 2.2 | 1.1 | 0.8 | -4.7 | 0.8 | 2.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 13 | 14 | 16 | 15 | 18 | 13 | 15 | 10 | 11 | 15 |
| Share Capital ⓘ | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves ⓘ | 3 | 3 | 5 | 4 | 7 | 3 | 4 | -1 | 1 | 4 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 60 | 64 | 64 | 52 | 70 | 56 | 58 | 58 | 36 | 53 |
| Long Term Debt | 48 | 50 | 50 | 18 | 39 | 45 | 47 | 48 | 29 | 40 |
| Short Term Debt | 13 | 15 | 14 | 34 | 31 | 11 | 11 | 11 | 7 | 12 |
| Trade Payables | 2 | 2 | 1 | 2 | 3 | 4 | 6 | 5 | 5 | 6 |
| Others Liabilities ⓘ | 1 | 1 | 2 | 7 | 10 | 14 | 16 | 22 | 39 | 24 |
| Total Liabilities ⓘ | 76 | 81 | 83 | 76 | 100 | 87 | 94 | 96 | 91 | 97 |
Fixed Assets | ||||||||||
| Gross Block | 25 | 25 | 25 | 26 | 27 | 27 | 28 | 29 | 41 | 44 |
| Accumulated Depreciation | 7 | 9 | 9 | 10 | 10 | 11 | 11 | 12 | 13 | 13 |
| Net Fixed Assetsⓘ | 18 | 17 | 16 | 17 | 16 | 17 | 17 | 17 | 28 | 30 |
| CWIP ⓘ | 0 | 0 | 0 | 6 | 9 | 10 | 12 | 12 | 2 | 0 |
| Investmentsⓘ | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Inventories | 5 | 6 | 5 | 9 | 10 | 11 | 11 | 9 | 9 | 10 |
| Trade Receivables | 4 | 4 | 5 | 6 | 7 | 9 | 9 | 10 | 10 | 12 |
| Cash Equivalents | 0 | 2 | 2 | 1 | 4 | 1 | 2 | 1 | 0 | 1 |
| Others Assetsⓘ | 38 | 42 | 43 | 25 | 42 | 29 | 31 | 35 | 30 | 33 |
| Total Assets ⓘ | 76 | 81 | 83 | 76 | 100 | 87 | 94 | 96 | 91 | 97 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 0 | 2 | 2 | -11 | 9 | 5 | -1 | 9 | 9 |
| PBT ⓘ | 2 | 3 | 4 | 3 | 3 | 4 | 2 | -1 | 7 | 7 |
| Adjustment ⓘ | 0 | 1 | 0 | 1 | 2 | -6 | 1 | 1 | 1 | 1 |
| Changes in Working Capital ⓘ | -3 | -3 | -2 | -3 | -17 | 12 | 1 | -1 | 1 | 1 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | -2 | -2 | -1 | -2 | -2 | -2 | -4 | -2 | 1 | -5 |
| Capex | -1 | 0 | 0 | -2 | -3 | -2 | -3 | -1 | -2 | -1 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | -1 | -1 | 0 | -1 | 1 | 0 | -1 | -1 | 3 | -4 |
| Cash Flow From Financing Activityⓘ | 1 | 3 | -2 | 1 | 16 | -11 | 0 | 2 | -11 | -3 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -6 | 2 | 0 | 1 | 21 | 6 | 2 | 8 | -19 | 12 |
| Interest Paid ⓘ | -1 | -1 | -1 | -1 | -2 | -2 | -1 | -6 | -6 | -4 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 8 | 2 | 0 | 0 | -4 | -15 | -1 | 0 | 14 | -11 |
| Net Cash Flow ⓘ | -1 | 2 | 0 | 0 | 3 | -4 | 1 | -1 | -1 | 0 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 7.96 | 8.08 | 11.65 | 14.44 | 14.16 | 7.69 | 6.98 | -53.02 | 11.64 | 29.02 |
| ROCE (%) | 3.45 | 3.56 | 4.61 | 5.96 | 7.04 | 5.06 | 3.71 | -0.61 | 10.19 | 10 |
| Asset Turnover Ratio | 0.37 | 0.39 | 0.43 | 0.5 | 0.5 | 0.5 | 0.59 | 0.46 | 0.6 | 0.67 |
| PAT to CFO Conversion(x) | 0 | 0 | 1 | 1 | -5.5 | 9 | 5 | N/A | 9 | 3 | Working Capital Days |
| Receivable Days | 56 | 51 | 50 | 53 | 56 | 63 | 61 | 80 | 66 | 65 |
| Inventory Days | 52 | 62 | 58 | 68 | 80 | 81 | 76 | 89 | 62 | 55 |
| Payable Days | 166 | 121 | 94 | 83 | 124 | 133 | 157 | 160 | 147 | 145 |
Kerala Ayurveda Ltd. (KAL) was founded on the banks of river Periyar at Aluva, Kochi, Kerala in 1945 by Late Vaidyan K G K Panicker, the renowned Ayurvedacharya. He was a doyen in Ayurvedic system, a visionary and a mentor. Now, more than half a century later, his inspired creation epitomizes all that is modern and state-of-the-art in Ayurveda. A leading Ayurvedic company today, KAL is backed by advanced technology and highly qualified dedicated staff.
Today Kerala Ayurveda is a major force in healthcare, growing at a spectacular rate -- with new clinics, new market strategies, new products, and new cures. Some of KAL's products are on the verge of being patented. KAL is truly on a mission to be the number one choice in Ayurveda globally.
Kerala Ayurveda has its world class manufacturing facility at Aluva, near Kochi. It also has a Herbarium.
The R&D Division of KAL has a prestigious herbal garden, which is actually a gene pool with more than 1200 species of rare and endangered medicinal plants, collected by conducting extensive surveys. These efforts also include certain hitherto unexplored tribal pockets, which are treasure groves of herbal wealth.
KAL has started its own Ayurvedic training center in view of propagating authentic Ayurveda. The training center, called KAL HRD CENTER is functioning as an annex to KAL Ayurveda Hospital at Aluva, near Kochi in Kerala. The center is easily assessable since it is located about 10 km, from the Nedumbassery International Airport (Cochin).The center is well equipped and conducts various training programme, various training Programs related with Ayurveda are offered by KAL HRD Center.
Publication Division- KAL has set up a publication division to publish Ayurvedic materials. An Ayurvedic quarterly journal named and styled as KAL VAIDYAM is published by this division. The division is designed to publish books, audio and video CDs and tapes on Ayurveda for the public and the scientific community.
Different offerings of the company:
Achievements/ recognition:
KAL Hospital, Aluva has been accredited with “Green Leaf†certification by Department of Tourism, Government of Kerala, which is the highest classification for outstanding quality of facilities and services.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
